Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 36.985
AS - Asia 22.706
EU - Europa 16.699
SA - Sud America 3.176
AF - Africa 526
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 39
Totale 80.184
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.085
SG - Singapore 7.887
CN - Cina 4.516
VN - Vietnam 4.023
IT - Italia 3.291
HK - Hong Kong 2.948
DE - Germania 2.720
RU - Federazione Russa 2.672
BR - Brasile 2.377
IE - Irlanda 1.780
SE - Svezia 1.726
UA - Ucraina 1.081
GB - Regno Unito 924
FR - Francia 746
IN - India 627
CA - Canada 595
FI - Finlandia 472
KR - Corea 385
TR - Turchia 358
BD - Bangladesh 340
ID - Indonesia 332
AR - Argentina 325
IQ - Iraq 238
PL - Polonia 216
ES - Italia 185
ZA - Sudafrica 183
JP - Giappone 173
MX - Messico 173
PK - Pakistan 167
AT - Austria 166
NL - Olanda 156
DK - Danimarca 120
SA - Arabia Saudita 114
EC - Ecuador 110
BE - Belgio 107
CO - Colombia 99
VE - Venezuela 94
PH - Filippine 88
UZ - Uzbekistan 80
MA - Marocco 77
CH - Svizzera 63
CL - Cile 58
EG - Egitto 50
TN - Tunisia 48
MY - Malesia 44
LT - Lituania 41
PE - Perù 41
AU - Australia 39
KE - Kenya 39
JO - Giordania 38
CZ - Repubblica Ceca 37
BG - Bulgaria 36
EU - Europa 32
PY - Paraguay 32
AE - Emirati Arabi Uniti 31
ET - Etiopia 31
IR - Iran 31
NP - Nepal 31
TH - Thailandia 28
RO - Romania 27
DO - Repubblica Dominicana 26
JM - Giamaica 25
AZ - Azerbaigian 24
CR - Costa Rica 23
PS - Palestinian Territory 20
BO - Bolivia 19
GR - Grecia 19
KG - Kirghizistan 19
OM - Oman 19
IL - Israele 18
KZ - Kazakistan 18
LB - Libano 18
PT - Portogallo 18
UY - Uruguay 18
DZ - Algeria 16
TW - Taiwan 16
NO - Norvegia 14
AL - Albania 13
MU - Mauritius 13
HN - Honduras 12
RS - Serbia 12
TT - Trinidad e Tobago 12
NZ - Nuova Zelanda 11
SY - Repubblica araba siriana 10
AO - Angola 9
LY - Libia 9
NG - Nigeria 9
NI - Nicaragua 9
PA - Panama 9
GE - Georgia 8
SK - Slovacchia (Repubblica Slovacca) 8
AM - Armenia 7
BH - Bahrain 7
EE - Estonia 7
KW - Kuwait 7
SC - Seychelles 7
CI - Costa d'Avorio 6
HR - Croazia 6
LA - Repubblica Popolare Democratica del Laos 6
LV - Lettonia 6
Totale 80.066
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Singapore 4.396
Ashburn 3.226
Hong Kong 2.876
Woodbridge 2.706
Fairfield 2.296
San Jose 1.792
Dublin 1.737
Houston 1.655
Frankfurt am Main 1.577
Chandler 1.490
Wilmington 1.323
Milan 1.307
Ho Chi Minh City 1.184
Jacksonville 1.050
Hanoi 970
Seattle 950
New York 881
Dearborn 794
Santa Clara 787
Cambridge 784
Los Angeles 663
Beijing 640
Hefei 615
Chicago 612
Dallas 596
Princeton 564
The Dalles 528
Seoul 359
Lauterbourg 328
Nanjing 320
Shanghai 306
Moscow 275
Altamura 249
Jakarta 249
Lawrence 249
São Paulo 247
Buffalo 234
Göttingen 188
Munich 176
Council Bluffs 175
Lachine 173
Helsinki 165
Da Nang 162
Guangzhou 158
San Diego 142
Boardman 131
Haiphong 130
Toronto 128
Nuremberg 126
Tokyo 126
Warsaw 122
London 120
Orem 118
Lissone 101
Vienna 101
Brussels 99
Andover 98
Nanchang 98
Shenyang 96
Ottawa 93
Dong Ket 91
Rome 90
Chennai 87
Montreal 87
Johannesburg 85
Rio de Janeiro 85
Baghdad 83
Fremont 81
Tianjin 78
Changsha 76
Hải Dương 74
Salt Lake City 72
Stockholm 72
Tashkent 71
Biên Hòa 70
Turku 69
Brooklyn 68
Denver 68
Hebei 68
Fürstenwalde 65
Dhaka 63
Atlanta 62
Kent 62
Romola 62
Poplar 60
Jinan 58
Can Tho 57
Jiaxing 57
Ninh Bình 57
Pune 57
Ha Long 56
Quận Bình Thạnh 55
Lappeenranta 53
Lodz 52
Phoenix 52
Curitiba 51
Istanbul 51
Mexico City 51
Lahore 50
Totale 52.621
Salva come PNG Salva come JPEG
Nome #
Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization 652
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 598
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 551
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 519
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 511
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 506
CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL – a retrospective study of the musthal cohort 483
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 457
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 451
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 450
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 445
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 445
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 443
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 442
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 439
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 435
Acute myeloid leukaemia niche regulates response to L-asparaginase 435
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 430
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 426
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 415
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 415
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 409
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 408
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 407
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 405
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 404
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 401
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 392
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 390
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 390
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 388
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 386
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 385
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 373
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 369
Idiopathic erythrocytosis: a germline disease? 365
Imatinib long term effects study: three years of follow-up and assessment 364
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 362
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 361
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 359
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 357
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 356
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 350
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 349
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 346
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 342
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 340
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 339
Whole-Exome Sequencing Data - Identifying Somatic Mutations 333
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 328
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 327
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 326
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 325
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 325
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 324
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 323
Chronic myeloid leukemia: Second-line drugs of choice 322
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 322
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 319
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 319
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 318
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 317
Inhibition of RET tyrosine kinase by SU5416 317
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 316
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 312
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 312
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 311
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 309
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 308
The ALK gene, an attractive target for inhibitor development 306
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 306
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 305
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 304
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 304
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 302
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 302
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 301
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 301
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 301
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 298
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 298
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 296
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 292
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 290
ALK inhibitors for clinical use in cancer therapy 290
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 289
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 287
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 286
Reply to P. Laneuville et al 284
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia 283
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 283
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 281
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 278
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 278
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 278
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 277
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 276
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 276
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 275
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 275
Totale 35.760
Salva come PNG Salva come JPEG
Categoria #
all - tutte 253.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 253.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.028 0 0 0 0 0 0 0 0 0 0 473 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/202513.373 790 1.498 734 665 1.115 506 914 419 1.112 1.954 1.217 2.449
2025/202628.167 4.223 2.279 2.407 3.481 3.379 1.628 4.446 1.382 2.449 2.448 45 0
Totale 81.990